Am J Psychiatry 160:284-289, February 2003
© 2003 American Psychiatric Association
Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With Schizophrenia
Martina C.M. Ryan, M.B., M.R.C.Psych.,
Patrick Collins, M.Sc., Ph.D., and
Jogin H. Thakore, M.B., Ph.D., M.R.C.Psych., M.R.C.P.I.
OBJECTIVE: This study examined the prevalence of impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. METHOD: In this cross-sectional study, fasting plasma levels of glucose, insulin, lipids, and cortisol were measured in 15 male and 11 female hospitalized Caucasian patients with DSM-IV schizophrenia (mean age=33.6 years) and age- and sex-matched healthy comparison subjects. The patients and comparison subjects were also matched in terms of various life-style and anthropometric measures. RESULTS: More than 15% of the drug-naive, first-episode patients with schizophrenia had impaired fasting glucose tolerance, compared to none of the healthy volunteers. Compared with the healthy subjects, the patients with schizophrenia had significantly higher fasting plasma levels of glucose (mean=88.2 mg/dl, SD=5.4, for the healthy subjects versus mean=95.8 mg/dl, SD=16.9, for the patients), insulin (mean=7.7 µu/ml, SD=3.7, versus mean=9.8 µu/ml, SD=3.9), and cortisol (mean=303.2 nmol/liter, SD=10.5, versus mean=499.4 nmol/liter, SD=161.4) and were more insulin resistant, as measured with homeostasis model assessment (mean=1.7, SD=0.7, for the healthy subjects versus mean=2.3, SD=1.0, for the patients). CONCLUSIONS: First-episode, drug-naive patients with schizophrenia have impaired fasting glucose tolerance and are more insulin resistant and have higher levels of plasma glucose, insulin, and cortisol than healthy comparison subjects.
This article has been cited by other articles:
|
|
|
|
 
G. BALF
Olanzapine Treatment and Weight Gain: Considering the Lipid Side Effects of Antipsychotics
Am J Psychiatry,
September 1, 2008;
165(9):
1206 - 1207.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hammerman, J. Dreiher, S. H Klang, H. Munitz, A. D Cohen, and M. Goldfracht
Antipsychotics and Diabetes: An Age-Related Association
Ann. Pharmacother.,
September 1, 2008;
42(9):
1316 - 1322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dickinson and P. D. Harvey
Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem
Schizophr Bull,
August 9, 2008;
(2008)
sbn097v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Pariante
Pituitary volume in psychosis: the first review of the evidence.
J Psychopharmacol,
March 1, 2008;
22(2 Suppl):
76 - 81.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. J. M. van Nimwegen, J. G. Storosum, R. M. E. Blumer, G. Allick, H. W. Venema, L. de Haan, H. Becker, T. van Amelsvoort, M. T. Ackermans, E. Fliers, et al.
Hepatic Insulin Resistance in Antipsychotic Naive Schizophrenic Patients: Stable Isotope Studies of Glucose Metabolism
J. Clin. Endocrinol. Metab.,
February 1, 2008;
93(2):
572 - 577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. F. Buckley, A. Foster, and B. Miller
Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics
Focus,
January 1, 2008;
6(2):
172 - 179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Stone and L. J. Seidman
Toward a Model of Memory Enhancement in Schizophrenia: Glucose Administration and Hippocampal Function
Schizophr Bull,
January 1, 2008;
34(1):
93 - 108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Kirkpatrick, E. Messias, P. D. Harvey, E. Fernandez-Egea, and C. R. Bowie
Is Schizophrenia a Syndrome of Accelerated Aging?
Schizophr Bull,
December 21, 2007;
(2007)
sbm140v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Venkatasubramanian, S. Chittiprol, N. Neelakantachar, M. N. Naveen, J. Thirthall, B. N. Gangadhar, and K. T. Shetty
Insulin and Insulin-Like Growth Factor-1 Abnormalities in Antipsychotic-Naive Schizophrenia
Am J Psychiatry,
October 1, 2007;
164(10):
1557 - 1560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.H. Barnett, P. Mackin, I. Chaudhry, A. Farooqi, R. Gadsby, A. Heald, J. Hill, H. Millar, R. Peveler, A. Rees, et al.
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
J Psychopharmacol,
June 1, 2007;
21(4):
357 - 373.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. R. Poa and P. F. Edgar
Insulin Resistance Is Associated With Hypercortisolemia in Polynesian Patients Treated With Antipsychotic Medication
Diabetes Care,
June 1, 2007;
30(6):
1425 - 1429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Lustman and R. E. Clouse
Depression in Diabetes: The Chicken or the Egg?
Psychosom Med,
May 1, 2007;
69(4):
297 - 299.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Goldberg, J. A. Kreyenbuhl, D. R. Medoff, F. B. Dickerson, K. Wohlheiter, L. J. Fang, C. H. Brown, and L. B. Dixon
Quality of Diabetes Care Among Adults With Serious Mental Illness
Psychiatr Serv,
April 1, 2007;
58(4):
536 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Citrome, A. Jaffe, J. Levine, and D. Martello
Incidence, Prevalence, and Surveillance for Diabetes in New York State Psychiatric Hospitals, 1997-2004
Psychiatr Serv,
August 1, 2006;
57(8):
1132 - 1139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T Lambert
Olanzapine is associated with more rapid weight gain than haloperidol in people with first episode psychosis.
Evid. Based Ment. Health,
August 1, 2006;
9(3):
72 - 72.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Lamberti, D. Olson, J. F. Crilly, T. Olivares, G. C. Williams, X. Tu, W. Tang, K. Wiener, S. Dvorin, and M. B. Dietz
Prevalence of the Metabolic Syndrome Among Patients Receiving Clozapine
Am J Psychiatry,
July 1, 2006;
163(7):
1273 - 1276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. B. Dickerson, C. H. Brown, G. L. Daumit, F. LiJuan, R. W. Goldberg, K. Wohlheiter, and L. B. Dixon
Health Status of Individuals With Serious Mental Illness
Schizophr Bull,
July 1, 2006;
32(3):
584 - 589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Chafetz, M. C. White, G. Collins-Bride, J. Nickens, and B. A. Cooper
Predictors of Physical Functioning Among Adults With Severe Mental Illness
Psychiatr Serv,
February 1, 2006;
57(2):
225 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Llorente and V. Urrutia
Diabetes, Psychiatric Disorders, and the Metabolic Effects of Antipsychotic Medications
Clin. Diabetes,
January 1, 2006;
24(1):
18 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rasmussen, M. J. Benvenga, F. P. Bymaster, D. O. Calligaro, I. R. Cohen, J. F. Falcone, S. K. Hemrick-Luecke, F. M. Martin, N. A. Moore, L. K. Nisenbaum, et al.
Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine
J. Pharmacol. Exp. Ther.,
December 1, 2005;
315(3):
1265 - 1277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dursun, T. G. Dinan, C. Bushe, and J. Thakore
Challenges in advancing mental and physical health of patients with serious mental illness
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
3 - 5.
[PDF]
|
|
|
|
|
|
|
C. Bushe, P. Haddad, R. Peveler, and J. Pendlebury
The role of lifestyle interventions and weight management in schizophrenia
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
28 - 35.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Tighe and T. Dinan
An overview of the central control of weight regulation and the effect of antipsychotic medication
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
36 - 46.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. I. G. Holt, C. Bushe, and L. Citrome
Diabetes and schizophrenia 2005: are we any closer to understanding the link?
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
56 - 65.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Citrome and D. Yeomans
Do guidelines for severe mental illness promote physical health and well-being?
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
102 - 109.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. H. THAKORE
Metabolic syndrome and schizophrenia
The British Journal of Psychiatry,
June 1, 2005;
186(6):
455 - 456.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Connolly and C. Kelly
Lifestyle and physical health in schizophrenia
Advan. Psychiatr. Treat.,
March 1, 2005;
11(2):
125 - 132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Henderson, E. Cagliero, P. M. Copeland, C. P. Borba, E. Evins, D. Hayden, M. T. Weber, E. J. Anderson, D. B. Allison, T. B. Daley, et al.
Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis
Arch Gen Psychiatry,
January 1, 2005;
62(1):
19 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. POUWER, R. LIEVERSE, M. DIAMANT, and J. ASSIES
Schizophrenia, Syndrome X, and Omega-3 Fatty Acids
Am J Psychiatry,
October 1, 2004;
161(10):
1926 - 1926.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Akhtar, C. Kelly, A. Gallagher, and J. R Petrie
Review: Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk
The British Journal of Diabetes & Vascular Disease,
September 1, 2004;
4(5):
303 - 309.
[Abstract]
[PDF]
|
|
|
|
|
|
|
O. D. Howes and L. Rifkin
Diabetic Keto-Acidotic (DKA) Coma following Olanzapine Initiation in a Previously Euglycaemic Woman and Successful Continued Therapy with Olanzapine
J Psychopharmacol,
September 1, 2004;
18(3):
435 - 437.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. I.G. Holt
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes: Response to consensus statement
Diabetes Care,
August 1, 2004;
27(8):
2086 - 2087.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Pariante, K. Vassilopoulou, D. Velakoulis, L. Phillips, B. Soulsby, S. J. Wood, W. Brewer, D. J. Smith, P. Dazzan, A. R. Yung, et al.
Pituitary volume in psychosis
The British Journal of Psychiatry,
July 1, 2004;
185(1):
5 - 10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Abel
Foetal origins of schizophrenia: testable hypotheses of genetic and environmental influences
The British Journal of Psychiatry,
May 1, 2004;
184(5):
383 - 385.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bushe and R. Holt
Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s67 - s71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. G. Dinan
Stress and the genesis of diabetes mellitus in schizophrenia
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s72 - s75.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Thakore
Metabolic disturbance in first-episode schizophrenia
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s76 - s79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Haddad
Antipsychotics and diabetes: review of non-prospective data
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s80 - s86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bushe and B. Leonard
Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s87 - s93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Peet
Diet, diabetes and schizophrenia: review and hypothesis
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s102 - s105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Diabetes Care,
February 1, 2004;
27(2):
596 - 601.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L Citrome and A. B Jaffe
Relationship of Atypical Antipsychotics with Development of Diabetes Mellitus
Ann. Pharmacother.,
December 1, 2003;
37(12):
1849 - 1857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Takore
Acute Stress Is Not Responsible for Glucose Dysregulation in Chronic Schizophrenia: Response to Shiloah et al.
Diabetes Care,
October 1, 2003;
26(10):
2967 - 2968.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2003
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
